USRM (USRM) Stock Price & Analysis
USRM (USRM) rose 0.00% to USD 0 as of June 10, 2026 at 03:29 UTC, according to Nexqual real-time market data.
USRM last closed at USD 0; the session ranged USD 0–0 on volume of 60,000 shares. Market capitalization is $64,150, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 03:29 UTC.
Key Statistics (as of June 10, 2026 at 03:29 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 60,000 shares |
| Market Cap | $64,150 |
| Exchange | PNK |
Technical Analysis (USRM)
Nexqual's technical model rates USRM "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:29 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (USRM)
Wall Street analysts rate USRM "None", per Nexqual as of June 10, 2026 at 03:29 UTC.
| Consensus Rating | None |
|---|
Earnings (USRM)
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Financials & Fundamentals (USRM)
| Total Revenue | $82,049 |
|---|---|
| Revenue Growth (YoY) | -15.30% |
| Gross Margin | +71.03% |
| Operating Margin | -1873.55% |
| Profit Margin | +0.00% |
| Current Ratio | 0.01 |
| Total Cash | $5,133 |
| Total Debt | $10.08M |
| Free Cash Flow | $-291,119 |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Financial Health Score (USRM)
Nexqual rates USRM's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:29 UTC.
| Growth | Critical — Revenue -15% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $5K cash vs $10M debt |
| Cash Flow | Weak — FCF negative: -$291K, burning cash |
| Efficiency | Mixed — No data |
Ownership (USRM)
| Insider Ownership | +10.95% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 641.51M |
| Float | 563.65M |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Leadership (USRM)
USRM is led by Michael Tomas (age 59), CEO, President, CFO & Director, per Nexqual as of June 10, 2026 at 03:29 UTC.
| CEO, President, CFO & Director | Michael Tomas (age 59) |
|---|---|
| Medical Director & Member of Scientific Advisory Board | Sergio Pinski |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VDRM | ViaDerma, Inc. | USD 0 | ▲ 0% |
| MMEX | MMEX Resources Corporation | USD 0 | ▲ 0% |
| OWCP | OWC PHARMACEUTICAL RESEARCH COR | USD 0 | ▲ 0% |
| RNVA | Rennova Health, Inc. | USD 0 | ▲ 0% |
| GAHC | Global Arena Holding, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:29 UTC. This page is informational and not investment advice.